Maturi RK, et al. - Herein, the continued intravitreous ranibizumab alone underwent a comparative analysis with ranibizumab plus intravitreous dexamethasone implant, in eyes with persistent diabetic macular edema (DME). It was revealed that though its use was more likely to reduce retinal thickness and increase intraocular pressure, the addition of intravitreous dexamethasone to continued ranibizumab therapy did not cause greater improvement in the visual acuity at 24 weeks than continued ranibizumab therapy alone among eyes with persistent DME following anti–vascular endothelial growth factor (anti-VEGF) therapy.